Page last updated: 2024-08-23

cabergoline and Cardiovascular Diseases

cabergoline has been researched along with Cardiovascular Diseases in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's3 (27.27)24.3611
2020's4 (36.36)2.80

Authors

AuthorsStudies
Kowalcze, K; Krysiak, R; Okopień, B3
Basiak, M; Krysiak, R; Machnik, G; Okopień, B; Szkróbka, W1
Descamps, P; Jeanneteau, P; Mercier, MB; Parot-Schinkel, E; Sentilhes, L1
Krysiak, R; Okopien, B1
Lamos, EM; Levitt, DL; Munir, KM1
Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM1
Beauchamp, MC; Li, L; Maingrette, F; Mamputu, JC; Renier, G; Serri, O1
Brändle, M; Schmid, C1
Arcoraci, V; Morgante, L; Savica, R; Tari, M; Trifirò, G1

Reviews

1 review(s) available for cabergoline and Cardiovascular Diseases

ArticleYear
A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
    Primary care diabetes, 2016, Volume: 10, Issue:1

    Topics: Animals; Biomarkers; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dopamine Agonists; Ergolines; Humans; Hypoglycemic Agents; Risk Factors; Treatment Outcome

2016

Trials

2 trial(s) available for cabergoline and Cardiovascular Diseases

ArticleYear
Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
    Basic & clinical pharmacology & toxicology, 2015, Volume: 116, Issue:3

    Topics: Adult; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Insulin Resistance; Insulin-Like Growth Factor I; Lipids; Middle Aged; Prolactin; Risk Factors

2015
The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
    Clinical endocrinology, 2006, Volume: 64, Issue:4

    Topics: Adult; Biomarkers; Blood Glucose; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; E-Selectin; Enzyme-Linked Immunosorbent Assay; Ergolines; Female; Humans; Hyperprolactinemia; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Linear Models; Lipids; Male; Middle Aged; Obesity; Risk Factors; Tumor Necrosis Factor-alpha

2006

Other Studies

8 other study(ies) available for cabergoline and Cardiovascular Diseases

ArticleYear
Cardiometabolic profile of young women with hypoprolactinemia.
    Endocrine, 2022, Volume: 78, Issue:1

    Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Carotid Intima-Media Thickness; Female; Fibrinogen; Genetic Diseases, Inborn; Glucose; Humans; Lactation Disorders; Prolactin; Risk Factors; Uric Acid

2022
Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
    Cardiology, 2022, Volume: 147, Issue:5-6

    Topics: Androgens; Atorvastatin; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Insulin Resistance; Pilot Projects; Prolactin; Risk Factors; Uric Acid

2022
Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
    Journal of clinical pharmacology, 2023, Volume: 63, Issue:8

    Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Cholesterol; Creatinine; Female; Fibrinogen; Glycated Hemoglobin; Hashimoto Disease; Humans; Hyperprolactinemia; Insulin Resistance; Lipoproteins, HDL; Prolactin; Risk Factors; Thyroiditis, Autoimmune; Uric Acid

2023
Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study.
    Nutrients, 2023, May-14, Volume: 15, Issue:10

    Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Glucose; Humans; Hyperprolactinemia; Pilot Projects; Prolactin; Risk Factors; Triglycerides; Uric Acid; Vitamin D; Vitamin D Deficiency; Vitamins

2023
[Inhibition of lactation: end to the bromocriptin, long life to the carbergolin?].
    Gynecologie, obstetrique & fertilite, 2014, Volume: 42, Issue:4

    Topics: Bromocriptine; Cabergoline; Cardiovascular Diseases; Ergolines; Female; France; Hormone Antagonists; Humans; Lactation

2014
The treatment of polycystic ovary syndrome.
    Minerva ginecologica, 2004, Volume: 56, Issue:1

    Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss

2004
The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
    Clinical endocrinology, 2006, Volume: 65, Issue:6

    Topics: Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Insulin Resistance; Obesity; Risk Factors

2006
Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Journal of the American Geriatrics Society, 2008, Volume: 56, Issue:2

    Topics: Aged; Antiparkinson Agents; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Male; Parkinson Disease; Pergolide; Treatment Outcome

2008